Affimed (AFMD) Posts Quarterly Earnings Results, Beats Expectations By $0.34 EPS
Affimed (NASDAQ:AFMD) issued its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.34, Morningstar.com reports. Affimed had a negative return on equity of 82.22% and a negative net margin of 2,124.72%.
Shares of AFMD stock opened at $4.32 on Thursday. The stock has a market capitalization of $253.93 million, a PE ratio of -5.54 and a beta of 3.39. The company has a quick ratio of 3.63, a current ratio of 3.66 and a debt-to-equity ratio of 0.06. Affimed has a 1-year low of $1.40 and a 1-year high of $7.35.
Hedge funds have recently modified their holdings of the company. D. E. Shaw & Co. Inc. bought a new position in Affimed in the fourth quarter worth approximately $36,000. Lindbrook Capital LLC bought a new position in Affimed in the fourth quarter worth approximately $38,000. CIBC World Markets Inc. bought a new position in Affimed in the third quarter worth approximately $104,000. FDx Advisors Inc. bought a new position in Affimed in the fourth quarter worth approximately $87,000. Finally, Geode Capital Management LLC boosted its holdings in Affimed by 29.0% in the fourth quarter. Geode Capital Management LLC now owns 66,074 shares of the biopharmaceutical company’s stock worth $205,000 after acquiring an additional 14,854 shares in the last quarter. 41.07% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Affimed (AFMD) Posts Quarterly Earnings Results, Beats Expectations By $0.34 EPS” was posted by Watch List News and is owned by of Watch List News. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://www.watchlistnews.com/affimed-afmd-posts-quarterly-earnings-results-beats-expectations-by-0-34-eps/2923508.html.
Affimed Company Profile
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Read More: Understanding Options Trading
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.